$10.69
+0.11 (+1.04%)
PMN News7 articles
Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027
Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.
D-Wave's Record Bookings Show Promise, Revenue Lag Remains Concern
D-Wave's Q1 bookings hit $33.4M, up 1,994%, driven by a $20M system sale. Revenue fell 81% to $2.9M, and net loss widened to $18.4M. Shares rose 6.47%.
Ernexa Therapeutics Surges 60% on Promising Ovarian Cancer Preclinical Data
Ernexa Therapeutics shares jumped about 60% after the company announced its ERNA-101 cell therapy plus PD-1 blockade eliminated tumors and achieved 100% long-term survival in preclinical ovarian cancer models.
Celcuity Surges 16% on Promising Breast Cancer Drug Data
Celcuity shares jumped 16% after its lead drug candidate, gedatolisib, met the primary endpoint in a Phase 3 breast cancer trial for PIK3CA-mutant tumors, setting the stage for a supplemental FDA filing.
Coinbase Shares Surge as Senate Compromise Revives Stablecoin Regulation Bill
Coinbase shares climbed Monday after a Senate compromise on stablecoin rewards revived the CLARITY Act, which had been stalled for months.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
JNJ Nears 52-Week Peak Amid Legal Win and Promising Heart Device Data
Johnson & Johnson shares approach a 52-week high after a New Jersey court disqualified a plaintiffs' firm from talc cases and the company released positive pilot data for its experimental atrial fibrillation platform.